INTRODUCTION {#s1}
============

Cancer has been the leading cause of worldwide mortality for many years and is a global health problem \[[@R1]\]. Despite tremendous advances in recent decades with regard to diagnostic techniques and therapeutic options, the prognosis of many cancers remains poor, especially in late stages. Clinicopathologic characteristics such as pathological grade and clinical stage are the main prognostic factors currently being used, but these parameters are often not reliably predictive of individual clinical outcomes. Therefore, identification of novel tumor biomarkers that can better predict cancer progression and prognosis is of vital importance.

B7-H3 (B7 homolog 3 protein) is a transmembrane glycoprotein and a member of the B7 family of proteins that was first described during analysis of a human dendritic cell (DC)-derived cDNA library \[[@R2]\]. B7-H3 has a critical function in antitumor immune responses \[[@R3]\], and evidence shows that B7-H3 possesses both co-stimulatory and co-inhibitory capacities in different tumor contexts. In addition, B7-H3 plays a non-immunological role in promoting cancer invasion and progression.

Overexpression of B7-H3 has been described in several cancers, and it was shown that B7-H3 expression is associated with clinicopathological factors and with prognosis in these cancers \[[@R4]--[@R13]\]. In some tumor types, high expression of B7-H3 has been linked to a poor prognosis, while in others the opposite relationship has been observed. Wu et al. \[[@R12]\] reported that B7-H3 expression correlates with a favorable prognosis in gastric cancer patients and suggested B7-H3 may promote an immune response. By contrast, Sun et al. \[[@R14]\] found that B7-H3 expression in non-small-cell lung cancer (NSCLC) correlates inversely with the number of tumor-infiltrating lymphocytes, which has the effect of promoting lymph node metastasis. Similarly, B7-H3 expression was identified as a poor prognostic factor in prostate cancer \[[@R15]\]. Thus, reports on the ability of B7-H3 to predict outcomes in various cancers are inconsistent. We therefore conducted a meta-analysis to assess the prognostic value of B7-H3 expression in cancer patients.

RESULTS {#s2}
=======

Characteristics of identified studies {#s2_1}
-------------------------------------

Twenty-eight studies published between 2007 and 2017 were included in our meta-analysis (Figure [1](#F1){ref-type="fig"}). A total of 4623 participants were analyzed to evaluate the relationship between B7-H3 expression and the prognoses of various tumors. Of this group, 3170 patients were positive for B7-H3 expression. The patients came from China, Japan, Austria, Norway, America and Germany and had been diagnosed with various cancers, including endometrial cancer, gastric carcinoma, cervical cancer, oral cancer, pancreatic cancer, osteosarcoma, esophageal cancer, colorectal cancer, breast cancer, hepatocellular carcinoma, ovarian carcinoma, lung cancer, prostate cancer, renal cell carcinoma (RCC), urothelial carcinoma of the bladder (UCB) and gallbladder cancer. Seven studies examined Caucasians, and 21 examined Asians. Twenty-six studies reported OS, 4 studies reported PFS, and 4 studies reported RFS. HRs and 95% CIs were directly reported in 15 studies and were calculated from survival curves in the other 13 studies. Cut-off values were different among the studies. The main characteristics of our included studies are presented in Table [1](#T1){ref-type="table"}.

![Flow diagram for the selection of studies in the meta-analysis](oncotarget-08-93156-g001){#F1}

###### Main characteristics of the studies in this meta-analysis

  Author                           Year   Country   Cancer           Case number   No. of B7-H3(+)   Detection method   Cut-off                                    Source of HR   Outcome measures   Follow-up (months)
  -------------------------------- ------ --------- ---------------- ------------- ----------------- ------------------ ------------------------------------------ -------------- ------------------ ---------------------------------------------------
  Xu et al. \[[@R6]\]              2010   China     NSCLC            102           71                IHC                NR                                         Reported       OS                 15--50
  Brunner et al. \[[@R13]\]        2012   Austria   Endometrial      99            29                IHC                IHS ≥ 9                                    SC             OS                 57(24--89)
  Wu et al. \[[@R12]\]             2006   China     Gastric          102           60                IHC                Average positive cell ratio \> 20%         Reported       OS                 NR
  Huang et al. \[[@R16]\]          2016   China     Cervical         108           78                IHC                IRS ≥ 3                                    Reported       OS                 36--96
  Chen et al. \[[@R17]\]           2015   China     Oral             72            48                IHC                NR                                         SC             OS                 NR
  Xu et al. \[[@R18]\]             2013   China     Pancreatic       45            35                IHC                IRS \> 3                                   SC             OS                 29.6(8--64)
  Wang et al. \[[@R19]\]           2013   China     Osteosarcoma     61            37                IHC                IRS \> 3                                   SC             OS                 60(24--87.60)
  Wang et al. \[[@R20]\]           2016   China     Esophageal       66            44                IHC                IRS \> 3                                   Reported       OS                 NR
  Chen et al. \[[@R21]\]           2015   China     Esophageal       174           97                IHC                H-score \> 185                             Reported       OS                 NR
  Mao et al. \[[@R22]\]            2013   China     Colorectal       98            45                IHC                Percentage of stained lymphocytes \> 20%   SC             OS                 NR
  Martin Loos \[[@R23]\]           2009   Germany   Pancreatic       68            28                IHC                IRS \> 3                                   SC             OS                 23(2--44)
  Maeda et al. \[[@R24]\]          2014   Japan     Breast           90            52                IHC                IRS \> 3                                   Reported       OS/RFS             67(7.8--90.5)
  Sun et al. \[[@R25]\]            2012   China     Hepatocellular   240           168               IHC                IRS: 2 and 3                               SC             OS/RFS             39 (1.5--95.0)
  Arigami et al. \[[@R26]\]        2011   Japan     Gastric          95            48                qRT-PCR            NR                                         Reported       OS                 24 (1--74)
  Zang et al. \[[@R15]\]           2007   USA       Prostate         803           746               IHC                NR                                         Reported       PFS                84(63.6--99.6)
  Zang et al. \[[@R10]\]           2010   USA       Ovarian          93            41                IHC                IHS \> 50                                  SC             OS                 Low stage: 96(7.2--306) High stage: 12(4.8--94.8)
  Chen et al. \[[@R27]\]           2014   China     Pancreatic       63            43                IHC                Stained tumor cells \> 10%                 SC             OS                 NR
  Jin et al. \[[@R28]\]            2015   China     NSCLC            110           60                IHC                NR                                         SC             OS                 6--60
  Liu et al. \[[@R29]\]            2012   Norway    Prostate         130           70                IHC                NR                                         Reported       PFS/RFS            84(14--279)
  Mao et al. \[[@R30]\]            2014   China     NSCLC            128           89                IHC                IRS ≥ 2                                    Reported       OS                 53.3(40.3--74)
  Zhou et al. \[[@R31]\]           2014   China     Colorectal       104           59                IHC                NR                                         SC             OS                 NR
  Boorjian et al. \[[@R32]\]       2008   USA       UCB              318           222               IHC                Stained tumor cells \> 10%                 Reported       OS/PFS             ≥ 120
  Ingebrigtsen et al. \[[@R33]\]   2014   Norway    Colorectal       731           637               IHC                NR                                         SC             OS/RFS             116.4(62.4--207.6)
  Luo et al. \[[@R34]\]            2017   China     Lung             46            37                IHC                Percentage of immunoreactivity \> 30%      Reported       OS                 NR
  Song et al. \[[@R35]\]           2016   China     Esophageal       100           66                IHC                Staining score \> 3                        Reported       OS/PFS             36(5.2--96)
  Fukuda et al. \[[@R36]\]         2016   China     RCC              181           90                ELISA              NR                                         Reported       OS                 31(3--100)
  Liu et al. \[[@R37]\]            2016   China     Gallbladder      126           84                IHC                Stained tumor cells \> 10%                 SC             OS                 NR
  Inamura et al.\[[@R38]\]         2017   Japan     Lung             270           86                IHC                Intensity 1 ≥ 50% or intensity 2 ≥ 10%     Reported       OS                 NR

NSCLC: non-small cell lung cancer; UCB: urothelial carcinoma of the bladder; RCC: renal cell carcinoma; IHC: immunohistochemistry; ELISA: enzyme-linked immunosorbent assay; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival; NR: no report; SC: survival curve; IRS: immunoreactivity score; IHS: immunohistochemical score; HR: hazard ratio; qRT-PCR: quantitative real-time fluorescence polymerase chain reaction.

B7-H3 expression and OS {#s2_2}
-----------------------

Twenty-six studies evaluating 3690 patients were submitted to OS analysis. Because statistical heterogeneity was observed among these studies (*I*^2^ = 47.1%, *P*~heterogeneity~ = 0.005), we used a random effects model to pool their HRs. The main results of this meta-analysis are presented in Table [2](#T2){ref-type="table"}. The pooled analysis showed that B7-H3 overexpression was significantly associated with worse OS in patients with solid tumors (pooled HR = 1.58; 95% CI = 1.32--1.90; *P* \< 0.00001) (Figure [2](#F2){ref-type="fig"}). Excluding two studies \[[@R6], [@R12]\] resolved the heterogeneity (*I*^2^ = 15.4%, *P*~heterogeneity~ = 0.248) (Figure [2](#F2){ref-type="fig"}), but we did not find sufficient clinical heterogeneity to justify their exclusion. To explore the source of the identified heterogeneity in these studies, we performed subgroup analyses by ethnicity, cancer type and source of HR. The subgroup analysis for ethnicity showed that B7-H3 expression was significantly associated with worse OS in Asians (pooled HR = 1.67; 95%CI = 1.38--2.04; *P* \< 0.00001), but not in Caucasians (pooled HR = 1.18; 95%CI = 0.84--1.66; *P* = 0.35); however, this difference was not statistically significant (*P*~D~ = 0.08) (Figure [3](#F3){ref-type="fig"}). The subgroup analysis based on tumor type showed that B7-H3 expression was significantly associated with worse OS for lung cancer (HR = 1.94; 95%CI = 1.31--2.87, *P* = 0.001), esophageal cancer (HR = 2.07; 95%CI = 1.19--3.59, *P* = 0.010) and other cancers including endometrial cancer, breast cancer, cervical cancer, oral cancer, osteosarcoma, hepatocellular cancer, ovarian cancer, RCC, UCB and gallbladder cancer (pooled HR = 1.53; 95% CI = 1.18--1.99; *P* = 0.001). However, there was no significant relationship between B7-H3 expression and OS in gastric cancer (HR = 0.80; 95% CI = 0.19-3.36; *P* = 0.759), pancreatic cancer (HR = 1.38; 95%CI = 0.74--2.55; *P* = 0.309), or colorectal cancer (HR = 1.02; 95%CI = 0.71--1.47; *P* = 0.901). Overall, the differences among cancer types were not statistically significant (*P*~D~ = 0.16) (Figure [3](#F3){ref-type="fig"}). Lastly, the subgroup analysis based on source of HR showed that differences between reported HRs and those based on survival curves were not statistically significant (*P*~D~ = 0.06) (Figure [3](#F3){ref-type="fig"}). To assess the stability of our results, we performed a sensitivity analysis by sequential omission of individual studies using a random effects model and found that the results were not clearly influenced by any single study ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). We also evaluated the publication bias of all included studies using funnel plots and Egger\'s and Begg\'s tests. Visual inspection of the funnel plots ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}) revealed no evidence of publication bias, which was confirmed by Begg\'s test (*P* = 0.186) and Egger\'s tests (*P* = 0.100).

###### Pooled HRs for overall survival and subgroup analysis of B7-H3 expression in cancer patients

                 No. of study   No. of patients   Random effects model   Heterogeneity   *P~D~* value   *P* value          
  -------------- -------------- ----------------- ---------------------- --------------- -------------- ----------- ------ ------------
  OS             26             3690              1.58                   1.32--1.90      0.005          47.1%              \< 0.00001
  Ethnicity                                                                                                         0.08   
  Caucasian      5              1309              1.18                   0.84--1.66      0.264          23.5%              0.350
  Asian          21             2381              1.67                   1.38--2.04      0.015          44.5%              \< 0.00001
  Tumor type                                                                                                        0.16   
  Lung           5              656               1.94                   1.31--2.87      0.009          70.3%              0.001
  Pancreatic     3              176               1.38                   0.74--2.55      0.449          0                  0.309
  Gastric        2              197               0.80                   0.19--3.36      0.007          86.2%              0.759
  Colorectal     3              933               1.02                   0.71--1.47      0.559          0                  0.901
  Esophageal     3              340               2.07                   1.19--3.59      0.112          54.4%              0.010
  Other          10             1388              1.53                   1.18--1.99      0.284          17.3%              0.001
  Source of HR                                                                                                      0.06   
  Reported       13             1780              1.80                   1.37--2.36      0.0003         66.5%              \< 0.0001
  SC             13             1910              1.29                   1.05--1.59      0.729          0                  0.014

OS: Overall survival; PFS: progression-free survival; RFS: recurrence-free survival; HR: hazard ratio; CI: confidence interval; PD: *P* value for subgroup difference; SC: survival curve.

![Forest plots of studies evaluating hazard ratios (HRs) of B7-H3 for overall survival\
(**A**) Summary of all twenty-six studies with regard to overall survival; the estimate was 1.58 (1.32--1.90) using a random effects model. (**B**) The exclusion of two studies \[[@R6], [@R12]\] resulted in no heterogeneity; the estimate was 1.49 (1.33--1.67) using a fixed effects model.](oncotarget-08-93156-g002){#F2}

![Forest plots of studies evaluating hazard ratios (HRs) of B7-H3 for overall survival in different subgroups\
(**A**) Subgroup analysis by ethnicity. (**B**) Subgroup analysis by cancer type. (**C**) Subgroup analysis by HR source.](oncotarget-08-93156-g003){#F3}

B7-H3 expression and PFS {#s2_3}
------------------------

Four studies evaluating 1351 patients underwent PFS analysis. Due to obvious statistical heterogeneity among these studies (*P*~heterogeneity~ = 0.062, *I*^2^ = 59.1%), we used a random effects model to pool their HRs. Our meta-analysis of these 4 studies revealed that B7-H3 expression was associated with poor PFS (HR = 1.67, 95%CI = 1.05--2.65, *P* = 0.031) (Figure [4](#F4){ref-type="fig"}).

![Forest plots of studies evaluating hazard ratios (HRs) of B7-H3 for PFS](oncotarget-08-93156-g004){#F4}

B7-H3 expression and RFS {#s2_4}
------------------------

Four studies evaluating 1191 patients underwent RFS analysis. A fixed effects model was used to pool their HRs because no obvious heterogeneity was observed among these studies (*P*~heterogeneity~ = 0.217; *I*^2^ = 32.6%). Our meta-analysis of these 4 studies showed that B7-H3 expression was not associated with RFS (HR = 1.17, 95%CI = 0.89-1.53, *P* = 0.267) (Figure [5](#F5){ref-type="fig"}).

![Forest plots of studies evaluating hazard ratios (HRs) of B7-H3 for RFS](oncotarget-08-93156-g005){#F5}

DISCUSSION {#s3}
==========

B7-H3, a member of the B7 family, was recently identified as an important co-stimulatory molecule that can be induced in B cells, T cells and DCs by a varity of inflammatory cytokines \[[@R2]\]. Although B7-H3 mRNA expression has been widely detected in human tissues, B7-H3 protein has rarely been found in normal tissues; instead, it is commonly detected on the surface of tumor cells \[[@R2]\]. Moreover, B7-H3 expression in tumor cells is associated with their migration, invasion and metastasis, ultimately leading to cancer progression \[[@R39], [@R40]\]. The precise physiological function of B7-H3 remains unclear. One early study showed that human B7-H3 functions as a co-stimulator of CD4+ and CD8+ T cells, promoting T cell proliferation and cytokine production *in vitro* \[[@R41]\]. However, most available data support the notion that B7-H3 inhibits T cell activation and proliferation \[[@R41]--[@R43]\]. Specifically, both the immunoglobulin-V-like and immunoglobulin-C-like forms of human B7-H3 inhibit T cell proliferation and reduce cytokine production in response to CD3/CD28-mediated co-stimulatory activation \[[@R43]\]. These findings indicate that B7-H3 can act as both a T cell activator and inhibitor.

By interfering with signaling pathways activated in non-immunological systems, B7-H3 promotes tumor progression, chemosensitivity and cancer metastasis. In the absence of lymphoid cells, Saran-mediated downregulation of B7-H3 significantly inhibited cancer cell migration and invasion, which suggests B7-H3 accelerates cancer progression via an unknown non-immunological mechanism \[[@R44]\]. B7-H3 expression correlates negatively with miR-29 levels, and the miR-29 binding site on B7-H3 mRNA is evolutionarily conserved, suggesting that a micro-regulatory mechanism influences B7-H3 expression profile at the mRNA and protein levels \[[@R45]\]. B7-H3 also appears to be involved in the Jak/Stat-3 pathway, which participates in multiple steps of metastasis, including invasion, survival, self-renewal, angiogenesis and immune evasion \[[@R46]\]. As Stat-3 is a convergence point for numerous signaling pathways and a valuable target for therapeutic intervention, a possible link between Stat3 and B7-H3 is of great interest.

Findings regarding the prognostic significance of B7-H3 in tumors have been controversial. Most studies suggested that high levels of B7-H3 expression in tumor cells were associated with disease progression and prognosis \[[@R8], [@R10], [@R11], [@R15], [@R25]\], but some reported no correlation between B7-H3 expression and tumor prognosis \[[@R47], [@R48]\]. Our results indicated that B7-H3 is highly expressed in 16 types of human cancer, and that high expression of B7-H3 is associated with poorer OS and PFS. However, our subgroup analysis showed that high B7-H3 expression was associated with poor OS in most cancers, but not gastric carcinoma, pancreatic cancer or colorectal cancer. The lack of consistency of these results may reflect differences in the methodologies used or differences in the function of B7-H3 in different cancers \[[@R16]\]. Although investigations have demonstrated the clinical significance of B7-H3 in different cancers, specific cognate receptors for B7-H3 have not been elucidated. The differing opposing effects of B7-H3 in different tumors may be associated with actions via different receptors, though this remains to be determined.

PD-L1 (B7-H1), another B7 family protein, suppresses immune responses by binding with PD-1 on T cells. Blocking the PD-1/PD-L1 pathway has led to significant clinical successes in a variety of cancers \[[@R49]--[@R51]\]. The expression pattern of B7-H3 and its functions differ from those of B7-H1. B7-H3 is mainly expressed on tumor cells and in the vasculature, while PD-L1 is expressed in immune cells, normal cells, and tumor cells \[[@R52]\]. B7-H1 expression in tumors often correlates with poor prognosis in cancer patients \[[@R53]--[@R55]\].

In addition to its immunological effects, B7-H3 can also promote cancer cell aggressiveness through various non-immunological pathways. Recently, antibodies targeting B7-H3 have been tested in several phase I/II clinical trials, and the results indicate B7-H3 is a promising target for future cancer immunotherapy. In addition, the relationship between B7-H1 and B7-H3 has been studied in some cancers. Chen et al. \[[@R27]\] showed that B7-H1 and B7-H3 promote pancreatic cancer progression, and their coexpression could be a valuable prognostic indicator. Mao et al. \[[@R30]\] found a positive correlation between expression of B7-H1 and B7-H3 in NSCLC and showed that expression of the two proteins is associated with poorer OS in patients with NSCLC. These findings suggest that treatments targeting B7-H3 and B7-H1 together may be a potential option for cancer immunotherapy.

There are several important implications of our meta-analysis. First, the results showed that B7-H3 overexpression is related to adverse OS and PFS in human solid tumors, indicating that B7-H3 may be a useful prognostic biomarker and therapeutic target for these tumors. Second, subgroup analysis based on cancer type showed that high B7-H3 expression is associated with poor OS in most cancers, but not some gastrointestinal cancers. The potential mechanism underlying this relationship is worthy of further study. Finally, B7-H3 has different functions in different cancers, which may reflect actions via different receptors. Inevitably, there are some limitations to our study. First, the numbers of studies and patients included in the PFS, RFS and OS subgroup analyses were relatively small, which could have resulted in heterogeneity. Second, the studies included in our analysis were all published in English, and thus some studies in other languages were omitted. Third, some studies did not provide accurate HRs for analysis, and we calculated HRs and 95% CIs based on survival curves, which resulted in small statistical errors. Finally, the cut-off values for B7-H3 expression differed among the included studies, which could have affected the stability of the results.

In conclusion, our results revealed that B7-H3 expression is associated with poor prognosis in most human solid tumors, suggesting that B7-H3 may be a useful prognostic biomarker and a promising new therapeutic target for solid tumors. In view of the limitations of our analysis, this conclusion should be considered cautiously. Some remaining questions and issues to be addressed in the future include identification of the exact receptors for B7-H3 and the establishment of standard assessment criteria. Accordingly, further prospective multicenter studies with larger samples will be needed to determine the role of B7-H3 in both the prognosis of and targeted therapy for various cancers.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

The PubMed and Embase databases were comprehensively searched until 11 February 2017. In this meta-analysis, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was followed \[[@R23]\]. The key words "B7-H3 OR CD276 OR B7 homolog 3 protein OR B7H3" AND "cancer OR tumor OR tumour OR neoplasm or carcinoma" AND "prognosis OR prognostic OR outcome OR survival OR fellow-up" were used to identify eligible studies. To identify additional potential studies, the reference lists of retrieved studies and reviews were also searched manually.

Eligibility criteria {#s4_2}
--------------------

Studies were included in our meta-analysis if they met the following criteria: (1) studies focusing on B7-H3 expression and survival outcome, and (2) studies published as a full paper in English. Studies were excluded according to the following criteria: (1) reviews, letters, case reports, conference abstracts and laboratory studies; (2) studies with duplicate data or repeated analysis; (3) studies lacking sufficient information for further analysis; and (4) studies of hematological malignancies (because these cancers have unique mechanisms for tumorigenesis and metastasis). PubMed and Embase were searched independently by two authors (X. Zhang and C. Fang). For dual publications, the most detailed and informative study was selected for inclusion in the meta-analysis; unpublished literature, conference proceedings, dissertations and trial registries were excluded.

Data extraction and quality assessment {#s4_3}
--------------------------------------

The following information was extracted independently by two investigators: first author\'s name, publication year, country of origin, cancer type, number of patients, gender and age of patients, detection method, cut-off value, statistical method for survival analysis, occurrence of B7-H3 expression, and HRs with corresponding 95% CIs for overall survival (OS), and/or progression-free survival (PFS), and/or recurrence-free survival (RFS). If a study reported results from both univariate and multivariate analyses, the data for the multivariate analysis were selected. If HRs and CIs were not reported, the outcomes of interest were independently calculated using Kaplan-Meier curves by two investigators according to methods proposed by Tierney et al. \[[@R56]\]. Both investigators compared their datasets and combined the results to yield a final dataset. Disagreements were resolved in a consensus meeting.

Each of the 28 eligible studies was evaluated for methodological quality according to the Newcastle-Ottawa Quality Assessment Scale (NOS) \[[@R57]\]. The mean value of all included studies was a score of 6.89 (ranging from 5 to 8) ([Supplementary Tables 1 and 2](#SD1){ref-type="supplementary-material"}), indicating high quality and good methodology. Therefore, all studies were included in the next meta-analysis.

Statistical analysis {#s4_4}
--------------------

HRs and corresponding 95% CIs obtained from the selected studies were used to calculate pooled HRs. Statistical heterogeneity was tested using the chi-square test, and the *I*^2^ statistic was used to assess the extent of statistical heterogeneity. If the *P* value was more than 0.1 for the chi-square test AND *I*^2^ was lower than 50%, indicating low heterogeneity, then a fixed effects model (the Mantel--Haenszel method) was used to calculate the pooled effect. Otherwise, a random effects model (the DerSimonian and Laird method) was used. Subgroup analyses were performed to explore the source of any identified heterogeneity, and sensitivity analyses were used to confirm the stability of the pooled results and to identify possible explanations for the observed heterogeneity. Publication bias was depicted by funnel plots and statistically assessed by Begg\'s and Egger\'s tests (with *P* \< 0.05 indicating significant publication bias). Statistical analysis was performed using STATA 12.0 software. A *P* value of less than 0.05 was defined as statistically significant. All *P* values were two-sided.
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